Kurz gefasst
Fachartikel in der Zeitschrift História e Cultura, 2026. Verfasst von Lindener Pareto Jr.. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This article analyzes the trajectory of a History communication program, "Provocação Histórica" (Historical Provocation), broadcast weekly on the digital channels of the Instituto Conhecimento Liberta (ICL) since January 2021, as a significant experience of Public History in contemporary Brazil. With over 265 interviews conducted with historians, intellectuals, and researchers from the humanities, the program has established itself as a space of mediation between academic historiographical production and broader audiences, operating at the intersection of Oral History, science communication, and digital communication. This work examines the program's genesis in the context of the COVID-19 pandemic, its methodology of long-form interviews, its positioning within the field of Brazilian Public History, and its contribution to the public debate on complex historiographical themes. Mobilizing theoretical frameworks on the digital turn in Oral History and the challenges posed by Social Media and Artificial Intelligence, it is argued that the program represents a form of epistemic resistance against presentism, denialism, and the attention fragmentation characteristic of digital platforms. The analysis demonstrates that it is possible to construct spaces for in-depth critical engagement within digital media, contributing to the formation of a more qualified public sphere and the strengthening of historical thinking as a tool for the critical understanding of the past and present.
Zitieren
APA
Jr., L. P. (2026). O PROVOCAÇÃO HISTÓRICA. História e Cultura. https://doi.org/10.18223/60f0fd47
Vancouver
Jr. LP. O PROVOCAÇÃO HISTÓRICA. História e Cultura. 2026. doi:10.18223/60f0fd47
BibTeX
@article{Jr2026,
author = {Jr., Lindener Pareto},
title = {O PROVOCAÇÃO HISTÓRICA},
journal = {História e Cultura},
year = {2026},
doi = {10.18223/60f0fd47}
}
EUVIMED